Ontario Institute for Cancer Research, Toronto, ON, Canada.
Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Nat Commun. 2022 Jan 11;13(1):208. doi: 10.1038/s41467-021-27889-y.
Cancer is often called a disease of aging. There are numerous ways in which cancer epidemiology and behaviour change with the age of the patient. The molecular bases for these relationships remain largely underexplored. To characterise them, we analyse age-associations in the nuclear and mitochondrial somatic mutational landscape of 20,033 tumours across 35 tumour-types. Age influences both the number of mutations in a tumour (0.077 mutations per megabase per year) and their evolutionary timing. Specific mutational signatures are associated with age, reflecting differences in exogenous and endogenous oncogenic processes such as a greater influence of tobacco use in the tumours of younger patients, but higher activity of DNA damage repair signatures in those of older patients. We find that known cancer driver genes such as CDKN2A and CREBBP are mutated in age-associated frequencies, and these alter the transcriptome and predict for clinical outcomes. These effects are most striking in brain cancers where alterations like SUFU loss and ATRX mutation are age-dependent prognostic biomarkers. Using three cancer datasets, we show that age shapes the somatic mutational landscape of cancer, with clinical implications.
癌症通常被称为衰老病。癌症流行病学和行为随着患者年龄的变化而发生诸多变化。这些关系的分子基础在很大程度上仍未得到充分探索。为了描述这些关系,我们分析了 35 种肿瘤类型的 20033 个肿瘤的核和线粒体体细胞突变景观中的年龄相关性。年龄会影响肿瘤中的突变数量(每年每兆碱基 0.077 个突变)及其进化时间。特定的突变特征与年龄相关,反映了外源性和内源性致癌过程的差异,例如年轻患者的肿瘤中烟草使用的影响更大,但老年患者的 DNA 损伤修复特征的活性更高。我们发现,已知的癌症驱动基因,如 CDKN2A 和 CREBBP,以与年龄相关的频率发生突变,这些突变会改变转录组并预测临床结果。这些影响在脑癌中最为明显,如 SUFU 缺失和 ATRX 突变是年龄相关的预后生物标志物。通过三个癌症数据集,我们表明年龄塑造了癌症的体细胞突变景观,并具有临床意义。